The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSPE.L Regulatory News (SPE)

  • There is currently no data for SPE

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

11 Dec 2019 07:00

RNS Number : 4343W
Sopheon PLC
11 December 2019
 

SOPHEON PLC

("Sopheon", the "Company" or the "Group")

 

TRADING UPDATE

 

Sopheon plc, the international provider of software and services for Enterprise Innovation Management and Strategy Execution Management, provides an update on the Group's performance for the year ended 31 December 2019.

 

In our interim results statement issued on 22 August 2019, we noted that we expected a more pronounced second half weighting to our annual performance, alongside a significantly expanded sales pipeline with a much higher than expected proportion of SaaS (Software as a Service) opportunities. That expectation has not changed. We entered the traditionally busy final quarter with over $30m1 in opportunities with 2019 target close dates, of which almost half related to SaaS deals and the balance in perpetual licenses along with associated consulting services. Today, overall revenue visibility2 for the year stands at $28m with $9.9m in remaining opportunities with 2019 target close dates. Of this, up to $2.7m represents perpetual license fees which, if signed, would contribute to recognized revenue in the current financial year. An additional $4.8m represents potential orders for multi-year SaaS or other recurring commitments, and the balance associated consulting services. December is traditionally a very busy month where we would expect to close a material number of deals and this would deliver a strong quarter in historic terms; however we would caution that our ability to execute on this is dependent on customers signing orders consistent with their plans as communicated to us, without unexpected internal delays.

 

In this regard, a number of the opportunities previously expected to sign in the fourth quarter have shifted to 2020. In some of these cases, Sopheon has already been selected as preferred vendor. The reasons for the extended buying cycles vary; some relate to extra scoping effort to expand the use of Accolade into a strategic purchase for the customer; others are due to customer specific factors such as M&A, personnel changes or budget consideration impacting decision making. Specific examples include a very substantial new SaaS deal with a top tier global customer, where Sopheon is the selected vendor but has since been held up due to customer resource availability due to another system implementation delay. At the other end of the scale, a mid-size perpetual license extension order from an existing customer has experienced delays due to an organizational restructure. The Company now expects both of these examples to sign in the first half of next year.

 

We have not seen a reduction in the overall size of our pipeline, rather a shift in the timing of conversion. The total forward pipeline for the balance of 2019 and 2020 has continued to grow and is now around 60% higher than at the end of 2018; we estimate that a third of this pipeline is SaaS related.

 

The Group's balance sheet also remains robust, with net cash as at the end of November 2019 at $19.2m.

 

Sopheon's Chairman, Barry Mence said: "The Board continues to believe that Sopheon is uniquely well placed to secure a leading position in the new and rapidly emerging enterprise solutions space of strategy execution management. This belief is undimmed by recent operating performance and conversion delays. Nevertheless, as a disciplined business, we have continued to tune costs in line with revenue wherever possible, while mindful of maintaining drive behind our strategic priorities. With a solid market position underpinned by a strong balance sheet and a strong pipeline, we continue to face the future with confidence and we fully intend to press on with our own strategic initiatives for long term growth and expansion."

 

As in previous years, a further update will be provided in January 2020.

 

1 Total deal value including software and service elements.

2 Revenue visibility is defined on page 7 of Sopheon's 2018 annual report which is available from the investor section of www.sopheon.com.

 

For further information contact:

Barry Mence (Chairman)Arif Karimjee (CFO)

Sopheon plc

+ 44 (0) 1276 919 560

Carl Holmes / Giles Rolls (Corporate Finance)Alice Lane / Sunila de Silva (ECM)

finnCap Ltd

+ 44 (0) 20 7220 0500

 

About Sopheon. Sopheon (LSE: SPE) partners with customers to provide complete enterprise innovation management solutions including software, expertise, and best practices, that enable them to achieve exceptional long-term revenue growth and profitability. Sopheon's Accolade solution provides unique, fully-integrated coverage for the entire innovation management and new product development lifecycle, including strategic innovation planning, roadmapping, idea and concept development, process and project management, portfolio management and resource planning. Sopheon's solutions have been implemented by over 200 customers with over 60,000 users in over 50 countries. Sopheon is listed on AIM, operated by the London Stock Exchange. For more information, please visit www.sopheon.com.

The information communicated in this announcement is inside information for the purposes of Article 7 of Regulation 596/2014.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTBBLLFKLFZFBX
Date   Source Headline
6th Dec 20137:00 amRNSDirector/PDMR Shareholding
5th Dec 20137:00 amRNSCorporate Update
19th Nov 20137:00 amRNSSopheon Delivers Accolade® Release 9.0
7th Nov 20137:00 amRNSInterim Management Statement
11th Sep 20133:00 pmRNSHolding(s) in Company
4th Sep 20133:00 pmRNSHolding(s) in Company
22nd Aug 20137:00 amRNSInterim Results
15th Aug 20133:00 pmRNSHolding(s) in Company
29th Jul 20133:00 pmRNSHolding(s) in Company
26th Jul 20137:00 amRNSTrading Update
15th Jul 20134:15 pmRNSHolding(s) in Company
28th Jun 20133:00 pmRNSTotal Voting Rights
27th Jun 20133:00 pmRNSHolding(s) in Company
19th Jun 20133:42 pmRNSHolding(s) in Company
19th Jun 20137:00 amRNSNew capabilities with Accolade(R) 8.3
14th Jun 20132:00 pmRNSContract Win
12th Jun 201312:00 pmRNSResult of AGM & GM
12th Jun 20137:00 amRNSAGM Statement
4th Jun 20137:00 amRNSIssue of Shares
2nd May 20137:00 amRNSInterim Management Statement
21st Mar 20137:00 amRNSPreliminary Results
30th Jan 20137:00 amRNSTrading Update
23rd Jan 20137:00 amRNSLaunch of Accolade 8.2
7th Dec 201211:36 amPRNHolding(s) in Company
8th Nov 20127:00 amPRNInterim Management Statement
1st Oct 20127:00 amRNSDirectors' Options
1st Oct 20127:00 amRNSHolding(s) in Company
24th Sep 20127:00 amRNSMarket Transfer to NYSE Alternext Concluded
23rd Aug 20127:00 amRNSAmendment to Terms of Convertible Loan Stock
23rd Aug 20127:00 amRNSInterim Results
23rd Jul 20127:00 amRNSTrading Update
13th Jun 20123:14 pmRNSResult of AGM
13th Jun 20127:00 amRNSAGM Statement
15th May 20127:00 amRNSAmendment to terms of Convertible Loan Stock
3rd May 20127:00 amRNSInterim Management Statement
25th Apr 20127:00 amRNSLaunch of Accolade 8.0
22nd Mar 20127:00 amRNSPreliminary Results
16th Feb 20127:00 amRNSTop 10 Solution Provider to CGM
31st Jan 20127:00 amRNSTrading Update
23rd Dec 201112:32 pmRNSExtension of GEM Equity Line
23rd Dec 201112:29 pmRNSTrading Update
5th Dec 201112:40 pmRNSHolding(s) in Company
3rd Nov 20117:00 amRNSInterim Management Statement
25th Aug 20117:00 amRNSInterim Results
25th Jul 20117:00 amRNSTrading Statement
23rd Jun 20112:15 pmRNSDirector/PDMR Shareholding
15th Jun 20117:00 amRNSAGM Statement
5th May 20117:00 amRNSInterim Management Statement
24th Mar 20117:00 amRNSPreliminary Results
10th Feb 20117:00 amPRNAppointment of Adviser

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.